Sensorion Completes Second Cohort Enrollment in OTOF Gene Therapy Clinical Trial
SENS-501 is a gene therapy candidate being developed to treat a form of congenital deafness linked to mutations in the OTOF (otoferlin) gene.
SENS-501 is a gene therapy candidate being developed to treat a form of congenital deafness linked to mutations in the OTOF (otoferlin) gene.